Bisphosphonate therapy for osteogenesis imperfecta
Background Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal
type I collagen bone matrix which typically results in multiple fractures with little or no …
type I collagen bone matrix which typically results in multiple fractures with little or no …
Juvenile idiopathic arthritis
A Ravelli, A Martini - The Lancet, 2007 - thelancet.com
Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group
of arthritides of unknown cause, which begin before 16 years of age. This term …
of arthritides of unknown cause, which begin before 16 years of age. This term …
The IOC consensus statement: beyond the female athlete triad—relative energy deficiency in sport (RED-S)
Protecting the health of the athlete is a goal of the International Olympic Committee (IOC).
The IOC convened an expert panel to update the 2005 IOC Consensus Statement on the …
The IOC convened an expert panel to update the 2005 IOC Consensus Statement on the …
2014 female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco …
The Female Athlete Triad is a medical condition often observed in physically active girls and
women, and involves three components:(1) low energy availability with or without …
women, and involves three components:(1) low energy availability with or without …
Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper
CA Migliorati, J Casiglia, J Epstein, PL Jacobsen… - The Journal of the …, 2005 - Elsevier
Background This position paper addresses the prevention of bisphosphonate-associated
osteonecrosis (BON) and the management of care of patients with cancer and/or …
osteonecrosis (BON) and the management of care of patients with cancer and/or …
Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy
CA Migliorati, MM Schubert, DE Peterson, LM Seneda - Cancer, 2005 - Wiley Online Library
BACKGROUND The current report presented 17 patients with cancer with bone metastases
and 1 patient with osteopenia who received treatment with bisphosphonates and who …
and 1 patient with osteopenia who received treatment with bisphosphonates and who …
Glucocorticoid-induced osteoporosis: who to treat with what agent?
R Rizzoli, E Biver - Nature Reviews Rheumatology, 2015 - nature.com
Among the adverse events of glucocorticoid treatment are bone loss and fractures. Despite
available, effective preventive measures, many patients receiving or initiating glucocorticoid …
available, effective preventive measures, many patients receiving or initiating glucocorticoid …
Clinical review: bisphosphonate use in childhood osteoporosis
LK Bachrach, LM Ward - The Journal of Clinical Endocrinology & …, 2009 - academic.oup.com
Context: As awareness of osteoporosis in childhood has increased, so have pressures to
consider use of the pharmacological agents used to treat osteoporosis in adults. This review …
consider use of the pharmacological agents used to treat osteoporosis in adults. This review …
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study
D Gatti, F Antoniazzi, R Prizzi, V Braga… - Journal of Bone and …, 2005 - academic.oup.com
In a randomized controlled study, we investigated the effect of treatment with intravenous
neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous …
neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous …
Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement
Bisphosphonates have been widely administered to children with OI based on observational
trials. A randomized controlled trial of q3m intravenous pamidronate in children with types III …
trials. A randomized controlled trial of q3m intravenous pamidronate in children with types III …